Profile data is unavailable for this security.
About the company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-104 is a multi-specific collaboration program for acute myeloid leukemia.
- Revenue in USD (TTM)5.86m
- Net income in USD-124.68m
- Incorporated2018
- Employees163.00
- LocationCentury Therapeutics Inc3675 Market StPHILADELPHIA 19104United StatesUSA
- Phone+1 (215) 981-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.centurytx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AC Immune SA | 4.35m | -76.68m | 173.13m | 126.00 | -- | 1.02 | -- | 39.83 | -0.9152 | -0.9152 | 0.0519 | 2.02 | 0.0195 | -- | 21.27 | 34,497.03 | -34.31 | -18.28 | -36.35 | -19.56 | -- | -- | -1,764.17 | -154.12 | -- | -- | 0.0171 | -- | -- | -27.94 | 3.06 | -- | -7.22 | -- |
| Atara Biotherapeutics Inc | 57.49m | -214.97m | 173.41m | 330.00 | -- | 2.63 | -- | 3.02 | -2.08 | -2.08 | 0.5589 | 0.6729 | 0.1644 | -- | 107.95 | 172,110.80 | -61.48 | -66.89 | -81.13 | -78.94 | 1.76 | -- | -373.95 | -1,664.51 | 3.22 | -- | 0.0127 | -- | 212.55 | -- | 32.88 | -- | -27.00 | -- |
| Kinnate Biopharma Inc | 0.00 | -122.31m | 173.72m | 94.00 | -- | 0.7798 | -- | -- | -2.75 | -2.75 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -41.29 | -- | -46.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.53 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -958.42k | 175.85m | 9.00 | -- | 0.6556 | -- | -- | -0.0725 | -0.0725 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -0.873 | -- | -0.888 | -- | -- | -- | -- | -- | -- | -- | 0.0202 | -- | -- | -- | -69.90 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -30.97m | 176.33m | 21.00 | -- | 1.78 | -- | -- | -0.2119 | -0.2119 | 0.00 | 0.6232 | 0.00 | -- | -- | 0.00 | -26.70 | -31.66 | -28.08 | -33.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.28 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -49.74m | 176.52m | 35.00 | -- | 1.40 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -45.36 | -- | -48.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.00 | -- | -- | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.68m | 178.25m | -- | -- | 9.32 | -- | -- | -0.1231 | -0.1231 | 0.00 | 1.34 | 0.00 | -- | -- | -- | -9.82 | -42.62 | -10.12 | -49.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.11 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 4.05m | -108.72m | 179.72m | 89.00 | -- | 0.6066 | -- | 44.43 | -2.26 | -2.26 | 0.0813 | 4.80 | 0.0149 | -- | 3.27 | 45,449.44 | -40.17 | -55.72 | -42.75 | -62.36 | -- | -- | -2,687.81 | -1,097.65 | -- | -- | 0.00 | -- | -66.90 | -- | -35.90 | -- | 0.57 | -- |
| Century Therapeutics Inc | 5.86m | -124.68m | 180.53m | 163.00 | -- | 0.6461 | -- | 30.80 | -2.14 | -2.14 | 0.1008 | 4.69 | 0.0117 | -- | -- | 35,957.05 | -24.77 | -- | -26.06 | -- | -- | -- | -2,127.33 | -- | -- | -84.52 | 0.0358 | -- | -- | -- | -36.64 | -- | -- | -- |
| Cara Therapeutics Inc | 43.24m | -84.39m | 183.54m | 106.00 | -- | 1.34 | -- | 4.24 | -1.57 | -1.57 | 0.8046 | 2.53 | 0.2293 | 2.87 | 10.10 | 407,943.40 | -44.75 | -31.98 | -49.33 | -36.56 | 82.02 | -- | -195.16 | -148.24 | 8.34 | -- | 0.00 | -- | 81.81 | 115.02 | 3.35 | -- | -5.81 | -- |
| ADC Therapeutics SA | 182.40m | -198.57m | 183.87m | 317.00 | -- | 4.88 | -- | 1.01 | -2.52 | -2.52 | 2.30 | 0.4673 | 0.3476 | 0.1423 | 7.18 | 575,400.60 | -37.84 | -47.88 | -44.24 | -54.34 | 98.83 | -- | -108.86 | -352.48 | 4.46 | -5.59 | 0.9001 | -- | 518.89 | 158.94 | 32.27 | -- | -6.15 | -- |
| Adaptimmune Therapeutics PLC - ADR | 71.17m | -114.16m | 183.93m | 534.00 | -- | 2.19 | -- | 2.58 | -0.7028 | -0.7028 | 0.4348 | 0.5065 | 0.2011 | -- | 40.20 | 133,284.60 | -32.25 | -40.76 | -39.49 | -47.20 | -- | -- | -160.39 | -701.17 | -- | -- | 0.00 | -- | 341.50 | -6.42 | -4.66 | -- | 3.52 | -- |
| GeneDx Holdings Corp | 223.89m | -533.07m | 184.49m | 1.10k | -- | 0.531 | -- | 0.824 | -44.48 | -44.48 | 16.72 | 13.58 | 0.4213 | 9.91 | 6.35 | 203,538.20 | -100.30 | -- | -126.43 | -- | -7.66 | -- | -238.09 | -- | 2.18 | -- | 0.0764 | -- | 10.60 | -- | -123.72 | -- | -- | -- |
| Aadi Bioscience Inc | 18.78m | -61.88m | 189.14m | 80.00 | -- | 1.30 | -- | 10.07 | -2.64 | -2.64 | 0.7824 | 5.97 | 0.12 | 0.8415 | 4.54 | 237,670.90 | -39.54 | -50.93 | -43.62 | -56.01 | 91.03 | -- | -329.56 | -405.07 | 9.08 | -- | 0.00 | -- | 1,258.57 | -- | 45.03 | -- | 118.57 | -- |
| Gracell Biotechnologies Inc (ADR) | 0.00 | -86.01m | 189.60m | 348.00 | -- | 0.9728 | -- | -- | -1.27 | -1.27 | 0.00 | 2.88 | 0.00 | -- | -- | -- | -32.69 | -- | -36.37 | -- | -- | -- | -- | -- | -- | -- | 0.1063 | -- | -100.00 | -- | -33.89 | -- | -- | -- |
| Immuneering Corp | 133.26k | -51.22m | 189.68m | 68.00 | -- | 1.76 | -- | 1,423.36 | -1.94 | -1.94 | 0.005 | 3.69 | 0.001 | -- | 0.9496 | 1,825.48 | -39.38 | -- | -40.82 | -- | 49.52 | -- | -38,437.16 | -- | -- | -- | 0.00 | -- | -84.76 | -- | -50.63 | -- | -- | -- |
Data as of May 26 2023. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD
29.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2023 | 5.29m | 8.94% |
| Casdin Capital LLCas of 31 Mar 2023 | 3.21m | 5.42% |
| DAFNA Capital Management LLCas of 31 Mar 2023 | 1.31m | 2.21% |
| BlackRock Fund Advisorsas of 31 Mar 2023 | 1.27m | 2.15% |
| Avidity Partners Management LPas of 31 Mar 2023 | 1.27m | 2.14% |
| Federated Global Investment Management Corp.as of 31 Mar 2023 | 1.16m | 1.97% |
| Baker Bros. Advisors LPas of 31 Mar 2023 | 1.15m | 1.94% |
| The Vanguard Group, Inc.as of 31 Mar 2023 | 1.09m | 1.84% |
| Deep Track Capital LPas of 31 Mar 2023 | 1.02m | 1.73% |
| Geode Capital Management LLCas of 31 Mar 2023 | 421.18k | 0.71% |
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
